Босния и Герцеговина - хорватский - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

evropa lijek pharma d.o.o. - gefitinib - film tableta - 250 mg/1 tableta - 1 film tableta sadrži: 250 mg gefitiniba

Черногория - хорватский - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"evropa lek pharma" doo podgorica - fingolimod - kapsula, tvrda - 0.5mg

Черногория - хорватский - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"evropa lek pharma" doo podgorica - pseudoefedrin, acetilsalicilna kiselina - granule za oralnu suspenziju - 30mg + 500mg

Черногория - хорватский - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"glk pharma" druŠtvo sa ograniČenom odgovornoŠĆu, podgorica - pseudoefedrin, ibuprofen - film tableta - 60mg + 400mg

Хорватия - хорватский - HALMED (Agencija za lijekove i medicinske proizvode)

pharmascience international limited, lampousas, 1, nicosia, cipar - azacitidin - prašak za suspenziju za injekciju - urbroj: jedna bočica s praškom sadrži 100 mg ili 150 mg azacitidina. nakon rekonstitucije 1 ml suspenzije sadrži 25 mg azacitidina.

Хорватия - хорватский - HALMED (Agencija za lijekove i medicinske proizvode)

pharmaswiss Česká republika s.r.o., jankovcova 1569/2c, prag, Češka - enalaprilum, lercanidipinum - filmom obložena tableta - 10 mg + 10 mg - urbroj: jedna tableta sadrži 10 mg enalaprilmaleata i 10 mg lerkanidipinklorida

Хорватия - хорватский - HALMED (Agencija za lijekove i medicinske proizvode)

pharmaswiss Česká republika s.r.o., jankovcova 1569/2c, prag, Češka - enalaprilum, lercanidipinum - filmom obložena tableta - 20 mg + 10 mg - urbroj: jedna tableta sadrži 20 mg enalaprilmaleata i 10 mg lerkanidipinklorida

Хорватия - хорватский - HALMED (Agencija za lijekove i medicinske proizvode)

ligula pharma d.o.o., iblerov trg 7, zagreb, hrvatska - meropenem trihidrat - prašak za otopinu za injekciju / infuziju - urbroj: jedna bočica sadrži meropenem trihidrat što odgovara 1000 mg bezvodnog meropenema

Хорватия - хорватский - HALMED (Agencija za lijekove i medicinske proizvode)

ligula pharma d.o.o., iblerov trg 7, zagreb, hrvatska - meropenem trihidrat - prašak za otopinu za injekciju / infuziju - urbroj: jedna bočica sadrži meropenem trihidrat što odgovara 500 mg bezvodnog meropenema

Европейский союз - хорватский - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.